{"id":49928,"date":"2014-09-19T14:23:54","date_gmt":"2014-09-19T18:23:54","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=49928"},"modified":"2014-09-19T19:44:31","modified_gmt":"2014-09-19T23:44:31","slug":"dont-ask-dont-tell","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2014\/09\/19\/dont-ask-dont-tell\/","title":{"rendered":"don’t ask, don’t tell…"},"content":{"rendered":"\n
It looks as if the Windy City of Chicago is taking the lead in figuring out if people are depressed without even asking them. Dr. Robert Gibbons of the University of Chicago is planning an an iPhone App that lets the cloud<\/em> figure it out [insider trading…<\/a>], and now Dr. Eva Redei of Northwestern’s Feinberg School of Medicine<\/em> adds a blood test<\/em> to the mix, launched in the pages of Time Magazine, no less, … <\/div>\n
\n
A Blood Test for Depression? Science Says It’s Possible<\/a><\/div>\n
TIME Magazine<\/font><\/strong><\/div>\n
Health Mental Health\/Psychology<\/div>\n
by Alice Park<\/div>\n
Sept. 16, 2014<\/div>\n

<\/p>\n

As with any disease, detecting depression early is critical for reducing suffering and for finding an effective course of treatment. Now, in a study released Tuesday, scientists led by Eva Redei at Northwestern Medicine say it may be possible to test for depression in the blood—and figure out which patients will benefit most from behavior-base<\/font>d the<\/font>rapy <\/font>as a <\/font>treat<\/font>ment.<\/font><\/div>\n<\/blockquote>\n
along with the Chicago Tribune<\/a>, the Huffington Post<\/a>, and Science Daily<\/a>.<\/div>\n
\n
First blood test to diagnose depression in adults<\/font><\/strong><\/div>\n
Date<\/font><\/strong>: September 17, 2014<\/div>\n
Source<\/font><\/strong>: Northwestern University<\/div>\n
Summary<\/font><\/strong>: The first blood test to diagnose major depression in adults has been developed, providing the first objective, scientific diagnosis for depression. The test also predicts who will benefit from cognitive behavioral therapy, offering the opportunity for more effective, individualized therapy. The test also showed the biological effects of the therapy, the first measurable, blood-based evidence of the therapy’s success and showed who is vulnerable to recurring episodes of depression…<\/div>\n<\/blockquote>\n
But that’s not all. If you’ve been treated with Cognitive Behavior Therapy,<\/em> either face-to-face or on the telephone, and you don’t know if it helped, their blood test will answer the question for you [or at least it panned out in the 64 subjects where they tried it]: <\/div>\n
\n
Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy<\/a><\/div>\n
by E E Redei, B M Andrus, M J Kwasny, J Seok, X Cai, J Ho and D C Mohr<\/div>\n
Translational Psychiatry.<\/font><\/strong> 2014 4:<\/strong>e442.<\/div>\n
Published online 16 September 2014<\/div>\n
[full text on-line<\/a>]<\/div>\n

<\/p>\n

An objective, laboratory-based diagnostic tool could increase the diagnostic accuracy of major depressive disorders [MDDs], identify factors that characterize patients and promote individualized therapy. The goal of this study was to assess a blood-based biomarker panel, which showed promise in adolescents with MDD, in adult primary care patients with MDD and age-, gender- and race-matched nondepressed [ND] controls. Patients with MDD received cognitive behavioral therapy [CBT] and clinical assessment using self-reported depression with the Patient Health Questionnaire–9 [PHQ-9]. The measures, including blood RNA collection, were obtained before and after 18 weeks of CBT. Blood transcript levels of nine markers of ADCY3, DGKA, FAM46A, IGSF4A\/<\/span>CADM1, KIAA1539, MARCKS, PSME1, RAPH1<\/em> and TLR7,<\/em> differed significantly between participants with MDD [N<\/em>=<\/span>32]<\/font><\/strong> and ND controls [N<\/em>=<\/span>32] <\/font><\/strong>at baseline [q<\/em>< 0.05]. Abundance of the DGKA, KIAA1539<\/em> and RAPH1<\/em> transcripts remained significantly different between subjects with MDD and ND controls even after post-CBT remission [defined as PHQ-9 <5]. The ROC area under the curve for these transcripts demonstrated high discriminative ability between MDD and ND participants, regardless of their current clinical status. Before CBT, significant co-expression network of specific transcripts existed in MDD subjects who subsequently remitted in response to CBT, but not in those who remained depressed. Thus, blood levels of different transcript panels may identify the depressed from the nondepressed among primary care patients, during a depressive episode or in remission, or follow and predict response to CBT in depressed individuals.<\/div>\n<\/blockquote>\n
You can read the full paper in Translational Psychiatry<\/a>, a peer reviewed, on-line only journal where the authors paid the price of admission<\/em>: <\/div>\n
\n
Open Access Publication<\/a><\/div>\n
Translational Psychiatry levies the following Article-Processing Charges [APC] [plus local taxes where applicable] per article accepted for publication. As the Creative Commons Attribution 3.0 Unported License grants greater end user rights including commercial reuse, papers published under this license will be charged at a premium APC. For more information on this license please see the press release.<\/div>\n<\/blockquote>\n
FEE SCHEDULE<\/font><\/strong><\/div>\n\n\n\n\n\n
License Type<\/font><\/strong><\/td>\nOriginal Article<\/font><\/strong><\/td>\nCorrespondence<\/font><\/strong><\/td>\n<\/tr>\n
…Noncommercial-Share Alike…<\/font><\/td>\n£2,200\/$3,600\/€2,600<\/font><\/td>\n£670 \/S1,000\/€800<\/font><\/td>\n<\/tr>\n
…Noncommercial-No Derivative…<\/font><\/td>\n£2,200\/$3,600\/€2,600<\/font><\/td>\n£670\/S1,000\/€800<\/font><\/td>\n<\/tr>\n
…<\/font>Commercial reuse<\/em>…<\/font><\/td>\n£2,400\/£3,900\/€2,800<\/font><\/td>\n£700\/$1,100 \/€900<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

It looks as if the Windy City of Chicago is taking the lead in figuring out if people are depressed without even asking them. Dr. Robert Gibbons of the University of Chicago is planning an an iPhone App that lets the cloud figure it out [insider trading…], and now Dr. Eva Redei of Northwestern’s Feinberg […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-49928","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/49928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=49928"}],"version-history":[{"count":45,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/49928\/revisions"}],"predecessor-version":[{"id":49997,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/49928\/revisions\/49997"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=49928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=49928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=49928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}